HBC Financial Services’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
$0 Hold
22
﹤0.01% 189
2024
Q3
$0 Sell
22
-126
-85% -$9.61K ﹤0.01% 181
2024
Q2
$11K Buy
148
+1
+0.7% +$67 0.01% 110
2024
Q1
$9K Buy
147
+2
+1% +$154 0.01% 111
2023
Q4
$11K Buy
145
+1
+0.7% +$78 0.01% 107
2023
Q3
$10K Buy
144
+2
+1% +$154 0.01% 112
2023
Q2
$11K Buy
142
+1
+0.7% +$80 0.01% 105
2023
Q1
$11K Buy
+141
New +$11.7K 0.01% 130
2020
Q4
Sell
-229
Closed -$13K 172
2020
Q3
$13K Buy
229
+3
+1% +$208 0.01% 120
2020
Q2
$15K Buy
226
+166
+277% +$12.7K 0.01% 98
2020
Q1
$4K Sell
60
-60
-50% -$4.15K ﹤0.01% 135
2019
Q4
$8K Buy
+120
New +$7.82K 0.01% 141

Other funds holding GILD

HBC Financial Services's GILD Position: Q4 2024 in Review

HBC Financial Services held its Gilead Sciences (GILD) position steady in Q4 2024 at 22 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #189.

HBC Financial Services first reported a position in GILD in Q4 2019 and has held it in 12 quarters since. The position peaked at $15K in Q2 2020. 1,890 funds tracked by Wall St. Rank hold GILD as of Q4 2024.

  • HBC Financial Services held 22 shares of Gilead Sciences worth $0 as of Q4 2024.
  • HBC Financial Services left its Gilead Sciences share count unchanged in Q4 2024.
  • Gilead Sciences made up ﹤0.01% of HBC Financial Services's portfolio in Q4 2024, its #189 holding.
  • HBC Financial Services first reported a position in Gilead Sciences in Q4 2019 and has held it in 12 quarters since.
  • HBC Financial Services's Gilead Sciences position peaked at $15K in Q2 2020.
  • 1,890 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2024.

Based on HBC Financial Services's 13F filing for Q4 2024, filed 16 Jan 2025.